The work matters because MASLD, which spans a spectrum from simple steatosis to inflammation, fibrosis, cirrhosis, and ultimately hepatocellular carcinoma, has no universally approved pharmacological therapy. Vitamin E has long been considered one of the few nutritional interventions with clinical evidence behind it, but most laboratory studies have relied on simplified single-cell cultures or animal models that poorly reflect human liver biology. The new study attempts to close that gap by building a model that incorporates both hepatocyte-like cells and hepatic stellate cells growing on a hydrogel derived from actual liver tissue.

The team, led by Seyedeh Kiana Teymoorian of the Royan Institute and the University of Science and Culture in Tehran, together with senior authors Massoud Vosough and Abbas Piryaei, constructed their model from two well-characterized human cell lines: Huh-7 hepatocyte-derived cells and LX-2 hepatic stellate cells, mixed at a ratio of four to one. This pairing is not arbitrary. In the living liver, hepatocytes store and metabolize fat, while stellate cells are the quiet fibroblasts that, when provoked by injury and inflammation, transdifferentiate into myofibroblast-like cells that produce collagen and drive fibrosis. Lipid overload in hepatocytes injures them, activates resident macrophages, and ultimately rouses the stellate cells into their fibrotic state, so a model that contains both cell types can capture at least one crucial axis of the disease that monocultures cannot.

What makes the platform distinctive is its substrate. The researchers coated the culture plates with LEMgel, a hydrogel prepared from decellularized sheep liver. To make it, they cut liver tissue into thin slices, stripped away all cellular material using detergents, freeze-dried the remaining scaffold, and dissolved it enzymatically in pepsin and acetic acid until a liquid at 10 milligrams per milliliter remained. Diluted to a coating concentration of 100 micrograms per milliliter, this preparation deposits a fibrous extracellular matrix, most likely rich in collagen, that provides both the structural texture and the biochemical signals of a real hepatic microenvironment. An MTS viability assay confirmed the coating was fully biocompatible, with no significant difference in cell survival between coated and uncoated plates.

With the stage set, the researchers induced disease by feeding the co-culture a fatty cocktail: 330 micromolar oleic acid and 165 micromolar palmitic acid, the two free fatty acids most abundant in the Western diet, delivered in complex with fatty acid-free bovine serum albumin. Two days of exposure produced robust and stable steatosis. Oil Red O staining, which dyes neutral triglycerides red, showed heavy intracellular lipid accumulation that persisted across six days of culture, and Nile Red fluorescence provided independent confirmation. Gene expression analysis sealed the diagnosis: carnitine palmitoyltransferase 1 (CPT-1), the rate-limiting transporter that shuttles long-chain fatty acids into mitochondria; SREBP-1c, the master transcription factor of de novo lipogenesis; and CD36, the fatty acid translocase on the cell surface, were all significantly upregulated compared with untreated controls. The co-culture was, in molecular terms, genuinely steatotic.

Then came the therapy. The team screened five doses of vitamin E, from 20 to 200 micromolar, and found that every dose reduced lipid accumulation, but concentrations of 100 micromolar and above cut it roughly in half compared with the fatty-acid-treated group. Because 100 micromolar achieved maximal benefit at the lowest effective concentration without any cytotoxicity, the researchers selected it for the full four-day treatment protocol. Cell viability, which had sagged under fatty acid exposure, rebounded significantly at every dose tested.

The molecular profile of the treated cells told a coherent story of recovery. Vitamin E downregulated CPT-1, NOX4, the NADPH oxidase enzyme that generates reactive oxygen species, along with SREBP-1c, CD36, and PPAR gamma, all drivers of lipid uptake and synthesis. Meanwhile it upregulated the antioxidant arm of the cellular defense: heme oxygenase 1 (HO-1) and NAD(P)H quinone dehydrogenase 1 (NQO1), two canonical downstream targets of the Nrf2 transcription factor, which functions as the master switch of the oxidative stress response. Superoxide dismutase and glutathione, two pillars of antioxidant chemistry, had both been depleted by fatty acid exposure; vitamin E restored glutathione levels significantly, although SOD secretion did not change measurably, suggesting the vitamin may act primarily through the glutathione system at this dose and duration.

The fibrosis axis of the model responded as well. Fatty acid treatment elevated ACTA-2, the gene encoding smooth muscle alpha actin, and COL1A1, the gene for type I collagen, both classic fingerprints of activated stellate cells. Vitamin E significantly reduced the expression of both. Consistent with this, transforming growth factor beta, the cytokine that activates LX-2 cells and propels fibrogenesis, rose sharply in the diseased model and fell dramatically after treatment. The researchers also tracked markers of hepatocyte maturity: albumin secretion, which had dropped under lipid stress, recovered with vitamin E, while alpha-fetoprotein, an indicator of immature or injured hepatocytes, had risen in the diseased state and fell to half its level after treatment.

At the protein level, Western blotting delivered perhaps the study’s most suggestive mechanistic finding. Both Nrf2 and CES1, a carboxylesterase that hydrolyzes triglycerides and cholesterol esters and sits downstream of Nrf2 signaling, were cut to roughly half their normal levels in the MASLD model. Vitamin E treatment restored both proteins to approximately control levels. Because CES1 governs the breakdown of stored fats, its suppression in fatty liver conditions directly promotes steatosis, and its recovery under vitamin E provides a plausible route by which the vitamin clears intracellular lipids. The authors are careful, however, not to overclaim: because they did not perform Nrf2 inhibition or knockdown experiments, they cannot conclude causally that all of vitamin E’s benefits flow through Nrf2, only that the pathway’s activation accompanied the therapeutic effects.

The physiological plausibility of the findings rests on well-established biochemistry. Vitamin E, a lipid-soluble antioxidant, intercalates into membranes where it neutralizes lipid radicals and interrupts the chain reaction of lipid peroxidation, a process central to the transition from simple steatosis to inflammatory steatohepatitis. Excess hepatic fat drives mitochondrial beta-oxidation into overdrive, flooding the cell with reactive oxygen species, overwhelming antioxidant defenses, stressing the endoplasmic reticulum, and pushing stellate cells toward fibrosis. By quenching radicals at their membrane source and simultaneously boosting Nrf2-driven enzymatic defenses, vitamin E attacks the vicious cycle at two points. The apparent reduction of CPT-1 expression after treatment, rather than an increase, the authors interpret as a sign that the compensatory stress response to lipid overload had subsided, an interpretation that reconciles their result with earlier mouse studies in which vitamin E raised CPT-1 while actively burning fat.

The study has honest limitations. The 2D co-culture omits Kupffer cells and other immune components that fuel inflammation in real livers, it relies on immortalized cell lines rather than primary human hepatocytes, and it lacks direct reactive oxygen species measurements. The authors suggest that future work with Nrf2 inhibitors, siRNA knockdown, primary cells, or organoid systems could firm up the mechanistic picture and extend the findings. Still, they position their platform as a pragmatic middle ground: far cheaper and faster than 3D organoids or animal studies, yet far more faithful to liver physiology than flat monocultures, because it combines cell-cell communication with tissue-derived extracellular matrix.

For a disease projected to become the leading indication for liver transplantation, and for which no drug has yet secured broad regulatory approval, accessible models that can rapidly screen candidate therapies are themselves a form of progress. The Tehran-Stockholm team’s platform, and the vitamin E data it generated, suggest that a humble vitamin, evaluated in a dish that looks and behaves a little more like a liver, can still teach the field something new.Subject of Research: Effects of vitamin E on oxidative stress, steatosis, and Nrf2 signaling in a biomimetic in vitro model of metabolic dysfunction-associated steatotic liver disease (MASLD)

The primary focus of the study is on the chemical constituents found within the bark of Ficus lyrata. Through a meticulous extraction and analysis process, the researchers identified several bioactive compounds that may be responsible for the observed health benefits. These compounds include flavonoids, tannins, and phenolic acids, which are well-known for their antioxidant, anti-inflammatory, and antimicrobial properties. The presence of these phytochemicals suggests that Ficus lyrata could serve as a valuable tool in combating oxidative stress, one of the main contributors to the onset and progression of NAFLD.

In the context of NAFLD, the role of oxidative stress is particularly critical. The accumulation of fat in the liver leads to an overload of free radicals, ultimately resulting in cellular damage and inflammation. This study posits that the antioxidant properties of Ficus lyrata bark extract may help mitigate these harmful effects by enhancing the body’s ability to neutralize free radicals. This presents an exciting avenue for further exploration, especially considering the limited treatment options currently available for NAFLD.

The inflammation associated with NAFLD is another pivotal area addressed in the research. Inflammation is not just a symptom; it exacerbates the condition by perpetuating liver damage. The study’s findings suggest that Ficus lyrata bark extract may possess anti-inflammatory effects, potentially through the inhibition of pro-inflammatory cytokines. By dampening the inflammatory response, this natural extract could herald a new approach to managing conditions like NAFLD, which affects millions worldwide.

Liver lipogenesis, the process by which the liver converts excess carbohydrates and proteins into fatty acids, is also a key factor in the development of NAFLD. Excessive lipogenesis leads to the storage of fat in liver cells, contributing to liver steatosis. The research highlights how Ficus lyrata bark extract may influence hepatic lipogenesis pathways. By regulating the enzymes involved in fat metabolism, this natural remedy could help maintain a healthy liver function, reducing the risk of fatty liver disease.

In conducting the study, rigorous methodologies were employed, including in vitro experiments that showcased the bark extract’s potential benefits. The researchers exposed liver cells to various concentrations of Ficus lyrata extract and monitored changes in markers of oxidative stress, inflammation, and lipid accumulation. The results were compelling, revealing a dose-dependent response, which underscores the importance of further research to establish optimal dosages and administration routes.

Furthermore, the interdisciplinary nature of this research highlights the need for collaboration between traditional medicine and modern scientific inquiry. Ficus lyrata has been used in folk medicine across various cultures, with anecdotal evidence supporting its health benefits. This study bridges the gap between these traditional uses and contemporary scientific validation, which could lead to increased acceptance and application of phytotherapy in clinical settings.

The implications of these findings extend beyond NAFLD. Given the increasing prevalence of metabolic diseases and the obesity epidemic, the potential for Ficus lyrata extract to serve as a multifunctional therapeutic agent is significant. By addressing oxidative stress, inflammation, and lipid dysregulation, this natural extract could become part of a comprehensive strategy to improve metabolic health and prevent liver-related disorders.

As the study progresses toward potential clinical application, additional research will be essential. Future clinical trials are necessary to determine the safety, efficacy, and recommended dosages of Ficus lyrata bark extract in human populations. Understanding how this extract interacts with other medications and dietary factors will also be crucial in developing practical guidelines for its use.

The interest in natural extracts as alternatives or complements to pharmaceutical interventions is more prominent than ever. Consumer demand for plant-based treatments is on the rise, reflecting a shift toward holistic health and wellness. Ficus lyrata, with its attractive profile and promising therapeutic benefits, fits perfectly into this emerging landscape of natural wellness.

Moreover, as research continues to unveil the impressive properties of various plant-derived compounds, the pharmaceutical industry is beginning to take notice. Integrating such natural sources into drug development could lead to innovative treatments for a wide array of conditions, not just liver diseases. The trend of exploring and harnessing nature’s bounty offers immense potential, making studies like this significant.

Efforts to promote the awareness of non-alcoholic fatty liver disease and other similar disorders should thus be bolstered by findings from such research. Increased public knowledge and education regarding lifestyle choices, dietary habits, and potential natural treatments could lead to improved health outcomes and quality of life for individuals affected by these conditions.

In conclusion, the exploration of Ficus lyrata bark extract and its potential in addressing oxidative stress, inflammation, and hepatic lipogenesis marks an exciting chapter in natural medicine. This study not only bridges traditional knowledge with modern science but also paves the way for innovative treatments for non-alcoholic fatty liver disease. As a community, we must look forward to the implications of these findings and their potential to transform how we manage metabolic health and disease prevention.

Subject of Research: Chemical profile of Ficus lyrata bark extract and its therapeutic effect on non-alcoholic fatty liver disease.

Article Title: Chemical profile of Ficus lyrata bark extract and its therapeutic effect on non-alcoholic fatty liver disease via regulating oxidative stress, inflammation and hepatic lipogenesis.

Article References: Mousa, A.M., Taher, R.F., El-Sammad, N.M. et al. Chemical profile of Ficus lyrata bark extract and its therapeutic effect on non-alcoholic fatty liver disease via regulating oxidative stress, inflammation and hepatic lipogenesis.
BMC Complement Med Ther 25, 280 (2025). https://doi.org/10.1186/s12906-025-05010-w

Image Credits: AI Generated

DOI: 10.1186/s12906-025-05010-w

Keywords: Ficus lyrata, non-alcoholic fatty liver disease, oxidative stress, inflammation, hepatic lipogenesis, phytotherapy, natural medicine.

Central to this research is 10-hydroxystearic acid (10-HSA), a bioactive compound synthesized by Lactobacillus species residing within the gut microbiome. The study employed murine models subjected to aflatoxin B1 (AFB1), a potent mycotoxin produced by Aspergillus fungi commonly contaminating staple crops such as peanuts and corn. Aflatoxin exposure is well-documented to induce hepatic injury and systemic inflammation, making it an ideal pathological trigger to investigate multimodal liver-gut interventions.

The intricate interplay between the gut and liver, commonly referred to as the gut-liver axis, has emerged as a critical focus of research in metabolic and inflammatory diseases. This bidirectional communication network hinges upon complex signaling pathways involving bile acids, immune effectors, and lipid metabolites which maintain homeostasis under physiological conditions. Dysregulation of this axis often manifests in diseases like NAFLD, where hepatic lipid accumulation coincides with compromised gut barrier function and heightened inflammatory responses.

In this study, treatment with 10-HSA demonstrated a robust therapeutic effect, reversing aflatoxin-induced pathologies by concurrently restoring the gut mucosal barrier and normalizing hepatic metabolism. The restoration of gut epithelial integrity is particularly significant given its role in preventing translocation of endotoxins and inflammatory mediators that exacerbate liver damage. Additionally, key bile acid metabolites, such as cholesterol and deoxycholate, which were perturbed under toxin exposure, returned to their physiological concentrations, signaling metabolic re-equilibration.

At the molecular level, 10-HSA exercises its protective effects through activation of peroxisome proliferator-activated receptor alpha (PPARα), a nuclear receptor pivotal in regulating fatty acid oxidation and energy homeostasis in hepatic tissue. Chronic liver diseases often involve suppression of PPARα signaling, contributing to lipid dysregulation and sustained inflammation. By reactivating this pathway, 10-HSA not only facilitates hepatic repair but also supports regulatory immune functions in the gut, showcasing a dual-organ therapeutic potential that has been elusive in previous pharmacological interventions.

Unlike many synthetic drugs that carry the risk of cytotoxicity or off-target effects, 10-HSA is a naturally derived metabolite produced endogenously by commensal bacteria, thereby offering an inherently safer profile. This highlights the strategic advantage of leveraging the microbiome’s bioactive repertoire as precision therapeutics that act in situ at inflammatory sites, delivering localized action with minimal systemic burden.

The implications of these findings extend beyond therapy for NAFLD. Aflatoxin exposure remains a global health threat, especially in agricultural communities with inadequate food safety infrastructure. Developing a microbiome-derived supplement based on 10-HSA could offer a transformative public health tool capable of mitigating the long-term deleterious effects of chronic aflatoxin ingestion, potentially reducing incidence of liver cancer and other related morbidities linked to toxin exposure.

This research shifts the paradigm from the traditional emphasis on short-chain fatty acids (SCFAs) to exploring more complex microbial metabolites produced in response to inflammatory stimuli within the gut ecosystem. Such molecules may hold a wealth of untapped therapeutic potential, particularly in diseases characterized by intertwined organ dysfunctions such as the gut and liver.

The team behind this pioneering work, led by Professor Satya Dandekar of UC Davis Health, is now advancing towards human clinical trials, aiming to validate efficacy and safety in patients with fatty liver disease and metabolic disorders. These upcoming studies may open new avenues for personalized biotherapeutics founded on symbiotic interactions between the human host and its microbiota.

The discovery of 10-HSA underscores the critical importance of the gut-liver axis as a drug target and the broader concept of microbiome pharmaceutics as a paradigm shift in managing chronic inflammatory diseases. By harnessing nature’s own medicinal chemistry crafted through host-microbe coevolution, this line of research heralds a future of innovative, safer, and more effective treatments that restore health by restoring balance.

In sum, this study not only elucidates the molecular mechanisms by which microbial metabolites orchestrate tissue repair across the gut-liver interface but also sets the stage for a new class of therapeutic agents grounded in the sophisticated metabolic interplay of our microbiome. As chronic liver diseases continue to surge globally, such insights offer hope for interventions that are as elegant as they are practical, merging microbiology with clinical hepatology in unprecedented ways.

Subject of Research: Animals

Article Title: Microbial biotherapeutic metabolite alleviates liver injury by restoring hepatic lipid metabolism through PPARα across the gut-liver axis

News Publication Date: 12-Aug-2025

Web References:
https://doi.org/10.1128/mbio.01718-25

Keywords: Liver damage, Microbiology, Gastrointestinal disorders, Digestive disorders, Gut microbiota, Probiotics, Human microbiota, Microorganisms, Microbial physiology, Bacteriology, Microbial ecology, Immune response, Mycology

Apoptosis, the programmed and orderly cellular self-destruction process, plays a pivotal role in NASH development and its subsequent HCC transformations. Hepatocyte apoptosis is markedly amplified during NASH, not merely as a consequence but as a driving force exacerbating liver injury, fibrosis, inflammation, and tumorigenesis. Intrinsic mitochondrial dysfunction characterizes this apoptotic escalation. In animal models, nicotine exposure has been demonstrated to downregulate CDGSH iron-sulfur domain-containing protein 3 (CISD3), impairing mitochondrial efficiency and heightening oxidative stress. This pathological cascade exacerbates hepatocyte apoptosis, underscoring CISD3 as an emerging therapeutic focus in NAFLD.

Delving deeper into intrinsic apoptotic regulation reveals the critical influence of the BCL-2 protein family. Mitochondrial outer membrane permeabilization (MOMP), a decisive event in apoptosis initiation, is orchestrated by these proteins. Innovative pharmacological approaches, such as the acridone derivative A22, manipulate the BCL-2 gene promoter’s unique i-motif structure, elevating BCL-2 expression and attenuating hepatocyte apoptosis. This breakthrough represents the pioneering endeavor to exploit gene promoter architectures for therapeutic benefit in NASH. Similarly, the anti-apoptotic factor Mcl-1 is regulated via a feedback loop involving PNPT1, which modulates its mRNA stability under lipid-rich conditions, influencing mitochondrial permeability and apoptosis.

The extrinsic apoptotic pathway is equally compelling in the NAFLD/NASH arena. BID, a pro-apoptotic BH3-only protein, has garnered attention for its capacity to instigate mitochondrial apoptotic signals. Advanced siRNA frameworks targeting BID have achieved marked therapeutic effects, reducing fibrotic progression and inflammatory sequelae in murine models by diminishing key mitochondrial effectors BAX and BAK. Another notable target, receptor-interacting protein kinase 1 (RIPK1), governs the extrinsic apoptotic cell fate decision. Post-translational modifications such as deSUMOylation by SENP1 temper RIPK1 activity, mitigating cellular susceptibilities to apoptosis and positioning RIPK1 as a node for therapeutic intervention.

Central executors of apoptosis—caspases—are not exempt from focused modulation strategies. Pan-caspase inhibitors like emricasan demonstrated robust suppression of apoptotic enzymes caspase 3 and 7 in clinical trials, alongside favorable safety and tolerability profiles, underscoring their clinical potential. Emerging selective inhibitors targeting caspase 2 have also shown promise in restraining the transition from NAFLD to NASH, exemplifying the sophisticated refinement of apoptotic modulation.

Parallel to apoptosis, necroptosis—a regulated necrotic form of cell death characterized by plasma membrane rupture—has surfaced as a critical contributor to NAFLD pathophysiology. Necroptotic execution is mediated chiefly through the RIPK1/RIPK3/MLKL signaling axis. Pharmacological inhibitors of RIPK1, such as necrostatin-1s and RIPA-56, have demonstrated efficacy in attenuating inflammation, fibrosis, and liver injury in murine models. RIPK3 inhibition similarly reduces hepatocyte necroptosis, modulating oxidative stress and inflammatory cascades, though its role is complex, underscored by epigenetic silencing in primary hepatocytes and variable expression profiles in disease states. This nuanced relationship necessitates patient-specific considerations for therapeutic targeting.

The terminal effector MLKL further consolidates necroptotic signaling, and its deficiency confers protective effects against NAFLD progression by dampening lipid synthesis and inflammatory chemokine expression. Regulatory nodes extending beyond direct necroptotic mediators, such as ER stress-related proteins Derlin-1 and transcription factors like ATF3 and FOXO1, have emerged as influential in modulating necroptosis, opening additional therapeutic horizons. Intriguingly, necroptosis also manifests in non-parenchymal liver cells including natural killer cells and liver sinusoidal endothelial cells, highlighting the systemic nature of regulated cell death in NASH.

Pyroptosis, an inflammatory form of programmed cell death triggered by inflammasomes and punctuated by cell lysis and pro-inflammatory cytokine release, represents a escalating focus in NASH research. The NLRP3 inflammasome is a linchpin in this context, mediating hepatocyte pyroptosis and perpetuating fibrotic remodeling. Pharmacological inhibition of NLRP3 via molecules such as CY-09, MCC950, and others not only mitigates lipid accumulation but also temper inflammation and fibrosis. Beyond NLRP3, other inflammasomes like AIM2 have been implicated, activated by mitochondrial DNA, adding layers of regulatory complexity.

Gasdermin D (GSDMD), the executor pore-forming protein in pyroptosis, is notably elevated in NASH, with gene knockout models exhibiting decreased hepatic inflammation and fibrosis. Caspases, specifically caspase-11 and caspase-1, serve as upstream activators of pyroptosis via GSDMD cleavage and inflammasome modulation, and their inhibition has been linked to ameliorated disease markers. Beyond these direct effectors, regulatory pathways involving transcription factors (e.g., NR5A2, p-STAT3), pattern recognition receptors (TLR4), and non-coding RNAs intricately orchestrate pyroptotic responses, suggesting multifaceted opportunities for pharmacologic intervention.

The intersection of metabolic regulation and cell death is further highlighted by the application of antidiabetic drugs. SGLT2 inhibitors, GLP-1 receptor agonists, and others have demonstrated modulation of apoptosis and pyroptosis pathways, reflected in altered caspase activity and inflammasome components. However, differential effects, such as metformin’s facilitation of helicase-mediated pyroptosis in leptin-resistant models, underscore the necessity for nuanced understanding of drug actions within metabolic and hepatic contexts.

More recently, PANoptosis has been conceptualized as a coordinated cell death program integrating apoptosis, necroptosis, and pyroptosis, regulated through complex sensor and effector protein networks. Evidence implicates mitochondrial dysfunction as a key initializer, with herbal formulations like Si-Wu-Tang exhibiting protective effects by preserving mitochondrial integrity and suppressing mtDNA-mediated activation of PANoptotic pathways. Key proteins such as ZBP1 facilitate PANoptosome assembly, though their roles in NAFLD/NASH remain unexplored, representing critical frontiers for mechanistic and therapeutic research.

Ferroptosis, an iron-dependent form of regulated necrosis driven by lipid peroxidation, is increasingly recognized for its role in amplifying inflammation and hepatocyte death in steatohepatitis. Inhibitors of lipid peroxidation and iron chelators demonstrate potent hepatoprotective effects by interrupting ferroptotic cascades. Regulatory nodes such as ACSL4 and GPX4 are central, with therapeutic modulation via small molecules, transcription factors like ATF4, and epigenetic regulators providing promising strategies to attenuate ferroptosis. The crosstalk between ferroptosis and metabolic dysregulation is profound, evidenced by scaffold proteins like EFHD2 in immune cells influencing ferroptosis and fibrosis progression and the impact of gut microbiota and diet-derived metabolites on ferroptotic pathways.

Cuproptosis, a nascent form of regulated cell death induced by aberrant copper metabolism, has recently been associated with NAFLD progression and its malignant transformation. Bioinformatic analyses have unveiled multiple cuproptosis-related genes implicated in disease severity and prognosis. Proteins such as FDX1, CTR1, and LIAS surface as pivotal regulators, affecting mitochondrial function, oxidative stress, and lipid metabolic homeostasis. Furthermore, compounds influencing copper handling and ion transport show therapeutic promise, while insights from studies in hepatic stellate cells and hepatocellular carcinoma broaden the potential applicability of cuproptosis-targeted therapies within the liver disease spectrum.

Collectively, the intricate landscape of regulated cell death pathways influencing NAFLD/NASH pathogenesis and progression to HCC underscores an era ripe for innovative therapeutic development. Targeting apoptosis, necroptosis, pyroptosis, PANoptosis, ferroptosis, and cuproptosis offers convergent strategies to disrupt hepatocyte injury, fibrosis, and tumorigenesis. As the field advances through integrating mechanistic insights, emerging technologies such as single-cell analytics, gene editing, and nanodelivery platforms promise to refine precision medicine approaches. Ultimately, unraveling the interconnected networks governing hepatic cell fate decisions holds the key to mitigating the global health burden imposed by metabolic liver diseases.

Subject of Research: Targeting regulated cell death pathways in the progression of NAFLD/NASH and hepatocellular carcinoma

Article Title: Killing hepatocellular carcinoma in the NAFLD/NASH stage: a comprehensive perspective on targeting regulated cell death

Article References:

Xi, J., Lei, S., Chen, J. et al. Killing hepatocellular carcinoma in the NAFLD/NASH stage: a comprehensive perspective on targeting regulated cell death.
Cell Death Discov. 11, 281 (2025). https://doi.org/10.1038/s41420-025-02558-x

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02558-x